IndexPage numbers followed by f or t indicate figures or tables, respectively.
AAbacavir, cutaneous side effects,
289t, 290-291Acitretin, for psoriasis, 243Acne
anatomy, 5-6, 6-7f�-defensins and, 366-367isotretinoin for, 2photodynamic treatment
advantages and disadvantages,3-5, 4t
algorithm, 25-26aminolevulinic acid–assisted, 8,
18-23, 18f, 20t, 22f, 23fapproaches, 8-11basis, 7-8blue-violet light, 13-15equipment, 4t, 26-27expected benefits, 25indocyanine green dye in, 23-24IPL, 16-17KTP laser, 17low fluence pulsed dye laser,
15-16low power density light, 12mid-infrared lasers, 24patient selection, 2, 25pulsed light, 12-13wavelength-specific penetration,
6-7f, 8-11, 9fwithout photosensitizer, 11-12
Acquired perforating dermatosis,narrowband ultraviolet-B for,240
Adalimumabcutaneous side effects, 285-289,
286tindications, 286
Aminolevulinic acid, for acne, 8,18-23, 18f, 20t, 22f, 23f
AMPs (see Antimicrobial peptides)Angioma, tufted, 210
Angiomatosis, diffuse dermal (seeDiffuse dermal angiomatosis)
Anthralin, for psoriasis, 242Anticoagulants, cutaneous side
effects, 294-296Anticonvulsants, cutaneous side
effects, 291-292Antimicrobial peptides (AMPs)
(see also �-defensins; Cathelicidins;Dermcidins)
bacterial resistance to, 369-370in cutaneous innate immune
response, 359-360Antiretroviral agents, cutaneous side
effects, 288-291, 289tAppendage tumors, cutaneous (see
Cutaneous appendage tumors)Atopic dermatitis
�-defensins and, 367-368chemokines and, 260-264, 261fhistopathology, 259-260leukocyte recruitment in, 261fnarrowband ultraviolet-B
for, 245-246AZT (see Zidovudine)
BBacterial resistance, to antimicrobial
peptides, 369-370Basal cell carcinoma, nail unit, 37-38�-defensins
in acne, 366-367in atopic dermatitis and psoriasis,
367-369direct antimicrobial activity, 365,
366fexpression, 364-365immune system potentiation by,
365-366in wound healing, 367
Blue nevi, dermal melanocyticproliferation in, 90
375
Blue rubber bleb nevus syndromeetiology, 180-181gastrointestinal involvement,
178-179hematologic abnormalities, 180histopathology, 180skin involvement, 178, 179ftreatment, 181
Blueberry muffin baby (seeViolaceous skin lesions,neonatal)
Brooke-Spiegler syndrome (seeFamilial cylindromatosis)
CCalcipotriene, for psoriasis, 241Capecitabine, cutaneous side effects,
285Cathelicidins
antineoplastic activity, 363congenital deficiency, 364in eccrine secretions, 362-363expression, 360mechanisms of antimicrobial
action, 360-361in saliva, 363structure, 360, 361fin warts, 363in wounds and bacterial infections,
361-362Cetuximab
cutaneous side effects, 282indications, 280
Chemokine receptors, T cells and,255-256
Chemokinesin atopic dermatitis, 260-264, 261fclassification, 252-253, 252fin cutaneous lupus erythematosus,
266-269, 268finteractions, 253-255, 254fin psoriasis, 262f, 263
Chemotherapyagents with cutaneous side effects
capecitabine, 285cetuximab, 282docetaxel, 285, 285f
erlotinib, 282gefitinib, 280-282, 281fimatinib, 283-284, 283fpaclitaxel, 285
for cutaneous squamous cellcarcinoma, 142
for melanoma of the nail unit, 55Chloroma, 157Churg-Strauss syndrome, 102Cockayne-Touraine strain, dystrophic
epidermolysis bullosa, 312,312f
(see also Dystrophic epidermolysisbullosa; Epidermolysis bullosa)
Collagen vascular disease,dermatologic manifestations(see Palisaded neutrophilic andgranulomatous dermatitis)
Comparative genomic hybridization(see Genomic analysis)
Congenital hemangiomas, 205Congenital leukemia (see Leukemia,
congenital)Congenital melanocytic nevi (see
Melanocytic nevi, congenital)COX-2 inhibitors (see
Cyclo-oxygenase-2 [COX-2]inhibitors)
Cutaneous appendage tumors(see also Familial cylindromatosis;
Spiradenoma;Trichoepithelioma)
histopathology, 218pathogenesis, 218treatment, 219
Cutaneous drug reactionsto adalimumab, 286t, 287to anticoagulants, 294-296to anticonvulsants, 291-292to antiretroviral agents, 288-291,
289tto capecitabine, 285to cetuximab, 282to cyclo-oxygenase-2 inhibitors,
292-294to dalteparin, 294-296, 295fto docetaxel, 285
376 Index
to enfuvirtide, 291to epidermal growth factor receptor
inhibitors, 280-282, 281fto erlotinib, 282to etanercept, 285-287, 286tto fusion inhibitors, 291to gefitinib, 280-282, 281fto imatinib, 283-284, 283fto infliximab, 285-287, 286tto lamotrigine, 292to low molecular weight heparins,
294-296to nonnucleoside reverse
transcriptase inhibitors,289-290, 289t
to nonsteroidal anti-inflammatorydrugs, 292-294
to nucleoside reverse transcriptaseinhibitors, 289t, 290-291
to paclitaxel, 285to protease inhibitors, 289, 289tto taxanes, 285to tumor necrosis factor-�
antagonists, 285-288, 286tCutaneous extravascular necrotizing
granuloma, 102Cyclo-oxygenase-2 (COX-2)
inhibitorscardiovascular risks, 293cutaneous side effects, 292-294
Cylindromatosis, familial(see Familial cylindromatosis)
DDalteparin, cutaneous side effects,
294-296, 295fDEB (see Dystrophic epidermolysis
bullosa)Defensins (see �-defensins)Dendritic cells
functions, 259migration, 257-258types, 258-259
Dermal-epidermal basementmembrane, molecular biology,305-306
(see also Epidermolysis bullosa)
Dermal hematopoiesis, 154-156, 155fDermcidins, 369Dermoscopy, in evaluation of
pigmented lesions of thenail unit, 49-50
Dialysis, nephrogenic fibrosingdermopathy and, 123
Diffuse dermal angiomatosis,116-118, 116f, 117f
Docetaxel, cutaneous side effects,285, 285f
Dowling-Meara variant,epidermolysis bullosa simplex,307
(see also Epidermolysis bullosa)DRESS
(see also Cutaneous drug reactions)with abacavir, 289t, 290-291
Dystrophic epidermolysis bullosa(DEB)
(see also Epidermolysis bullosa)characteristics, 311-312dominant
of Cockayne-Touraine, 312, 312fof Pasini, 313
inheritance pattern, 304tpathogenesis, 313-318pruriginosa, 313recessive
Hallopeau-Siemens (RDEB-HS),313, 314f, 321, 322t
mitis, 313
EEB (see Epidermolysis bullosa)EBHD (see Hemidesmosomal
epidermolysis bullosa)EBS (see Epidermolysis bullosa
simplex)Eccrine spiradenoma (see
Spiradenoma)EGF-R (epidermal growth factor
receptor) inhibitors,cutaneous side effects,280-282, 281f
Enfuvirtide, cutaneous side effects,289t, 291
Index 377
Epidermal growth factor receptor(EGF-R) inhibitors, cutaneousside effects, 280-282, 281f
Epidermal stem cellsadhesion properties, 345-346assays
adhesion studies, 341grafting studies, 341-342label-retaining cell studies, 341in vitro cultures, 339-340in vivo, long-term repopulation,
342-345, 344tepidermal proliferation units and,
337frequency, 336-337hair follicle bulge as site of,
347-348hierarchy, 348-349, 349fmolecular signature, 348multipotency, 337-339, 338fproliferative properties, 346-347side population cells, 347
Epidermolysis bullosa(see also Dystrophic epidermolysis
bullosa; Epidermolysis bullosasimplex; Hemidesmosomalepidermolysis bullosa;Junctional epidermolysisbullosa)
classification, 304tdiagnosis, 317-318genetic counseling and prenatal
diagnosis, 319history, 304-305molecular biology, 305-306molecular defects, 305, 305ttreatment
cutaneous manifestations, 319-321extracutaneous manifestations,
322-323, 322tmolecular therapy, 324-325systemic therapy, 323
Epidermolysis bullosa simplex (EBS)(see also Epidermolysis bullosa)characteristics, 306extracutaneous manifestations, 322t
generalized (Koebner), 306-307,307f
inheritance pattern, 304tlocalized (Weber-Cockayne), 307,
308fwith mottled pigmentation,
308-309of Ogna, 308pathogenesis, 309-310
Erlotinibcutaneous side effects, 282indications, 281
Erythema, necrolytic acral (seeNecrolytic acral erythema)
Etanerceptcutaneous side effects, 285-288,
286tindications, 285-286
Etretinate, for psoriasis, 243
FFamilial cylindromatosis
clinical features, 220, 221fgenomic analysis, 219-220, 223histopathology, 220-223, 222fhistory, 219-220pathogenesis, 223-226, 225f
Fusion inhibitors, cutaneous sideeffects, 289t, 291
GGefitinib
cutaneous side effects, 280-282,281f
indications, 280Generalized atrophic benign
epidermolysis bullosa(GABEB), 316-317, 322t
(see also Epidermolysis bullosa;Hemidesmosomalepidermolysis bullosa)
Genomic analysiscomparative genomic hybridization
of blue nevi, 90of congenital melanocytic nevi, 89diagnostic applications, 93-96,
94f, 96f
378 Index
of familial cylindromatosis, 223of melanoma, 90-93, 92tmethod, 84-86, 84fof Spitz nevi, 86-89, 87f, 88f, 197
karyotyping, 83-84Glomangioma/glomuvenous
malformationclinical features, 184-185, 184thistopathology, 183-184inheritance pattern, 181-182skin involvement, 182, 183fsystemic involvement, 182-183treatment, 185
HHair follicle, as epidermal stem cell
site, 347-348Hallopeau-Siemens, variant of
recessive dystrophicepidermolysis bullosa, 313,314f
(see also Epidermolysis bullosa)Hallopeau-Siemens variant, recessive
dystrophic epidermolysisbullosa
(see also Dystrophic epidermolysisbullosa)
Hands, neutrophilic dermatosis (seeNeutrophilic dermatosis, dorsalhands)
HBD (see �-defensins)Heart transplant recipients,
cutaneous squamous cellcarcinoma in, 144, 145f
Hemangioendothelioma, kaposiform,208-209, 209f
Hemangiomas, infantileclinical features, 175, 176f,
202-203, 203fcongenital, 205, 206fetiology, 201-202genetic alterations in, 202histopathology, 175-176, 204-205,
204fincidence, 202vs. other vascular anomalies,
199-201, 200t, 201t
treatment, 176Hemangiopericytomas, infantile,
173-175, 174fHematopoiesis, dermal, 154-156,
155fHemidesmosomal epidermolysis
bullosa (EBHD)(see also Epidermolysis bullosa)characteristics, 315-316generalized atrophic benign
(GABEB), 316-317, 322tinheritance pattern, 304twith muscular dystrophy, 316with pyloric atresia (EBHD-PA), 317
Hepatitis C virus, in necrolyticacral erythema, 112, 114
Herlitz variant, junctionalepidermolysis bullosa, 310
(see also Epidermolysis bullosa;Junctional epidermolysisbullosa)
HistiocytosisLangerhans cell (see Langerhans
cell histiocytosis)non-Langerhans cell, 172-173, 172f
Human immunodeficiency virus(HIV) infection, squamouscell carcinoma in, 135-136
Human papillomavirus (HPV),squamous cell carcinoma ofthe nail bed and, 38-40, 40f
II�B, in familial cylindromatosis, 224Imatinib
cutaneous side effects, 283-284,283t
indications, 283Immunity, cutaneous
antimicrobial peptides in, 359-360(see also �-defensins;Cathelicidins; Dermcidins)
Toll-like receptors in, 359Immunosuppression, squamous cell
carcinoma and, 135-136
Index 379
Indinavir, cutaneous side effects,289, 289t
Indocyanine green dye, inphotodynamictreatment of acne, 23-24
Infliximab, cutaneous side effects,285-289, 286t
Injection site reactions(see also Cutaneous drug reactions)to adalimumab, 287to etanercept, 287, 288f
IPL, in photodynamic treatment ofacne, 16-17
Isotretinoin, for acne, 2
JJEB (see Junctional epidermolysis
bullosa)Jessner’s lymphocytic infiltrate of the
skin, 122Junctional epidermolysis bullosa
(JEB)(see also Epidermolysis bullosa)characteristics, 310extracutaneous manifestations, 322tgravis (Herlitz), 310inheritance pattern, 304tmitis, 310, 311fpathogenesis, 311
Juvenile xanthogranulomas, 172-173,172f
KKaposiform hemangioendothelioma,
208-209, 209fKaryotyping, 83-84Kasabach-Merritt phenomenon,
206-207, 207fKoebner variant, epidermolysis
bullosa simplex, 306-307,307f
(see also Epidermolysis bullosa;Epidermolysis bullosasimplex)
KTP laser, in photodynamictreatment of acne, 17
LLamotrigine, cutaneous side effects,
292Langerhans cell histiocytosis
clinical features, 168, 169tcongenital self-healing, 168-169,
170fhistopathology, 169-171historical terms for, 165prognosis, 168, 171skin involvement, 165-168, 166f,
167f, 168ftreatment, 171-172
Lasers, for acne treatmentIPL, 16-17KPT, 17low fluence pulsed dye, 12-13,
15-16mid-infrared, 24wavelength-specific skin
penetration, 10-11Leukemia, congenital
chromosomal abnormalities, 159diagnostic criteria, 157etiology, 156-157histopathology, 158incidence, 156prognosis, 158-159skin involvement, 157-158, 158f
Lichen planus, narrowbandultraviolet-B for, 245
Light treatmentfor acne (see Acne, photodynamic
treatment)for psoriasis (see Psoriasis,
narrowband ultraviolet-Bphototherapy)
LL-37/hCAP18 (see Cathelicidins)Longitudinal melanonychia, 74-75Low molecular weight
heparins, cutaneous sideeffects, 294-296, 295f
Lupus erythematosuscutaneous, chemokines in, 266-269,
268fdrug-induced, 286-287
380 Index
leukocyte recruitment in, 268ftumid (see Tumid lupus
erythematosus)Lymphangioendotheliomatosis,
multifocal, 176-178, 177fLymphoma, cutaneous T-cell,
narrowband ultraviolet-Bfor, 243-244
MMalignant glomus tumors, nail unit,
56Melanocytic nevi
congenitalbenign proliferative nodules in,
70, 70fcategories, 66-67genomic and genetic changes in,
89incidence, 66melanoma risk and, 67-68, 68tneurocutaneous melanosis
in, 70-72, 72fprophylactic measures, 68-70, 69t
genomic differences inbenign vs. malignant, 90-91diagnostic application, 95-96, 96f
longitudinal melanonychia,74-75, 74f
MELTUMPs, 77-78occult spinal dysraphism and,
72-74, 73f, 73tSpitz nevi (see Spitz nevi)
Melanomaof childhood (see Spitz nevi)genomic and genetic changes in
vs. benign melanocytic nevi,86, 87f, 90-91
diagnostic application, 93-95, 94fby type, 91-93, 92t
nail unitdiagnosis, 48-52, 48f, 50tetiology, 47-48histology, 51-52incidence, 46-47longitudinal melanonychia and,
74-75, 74f
staging, 52-53treatment, 53-56
risk in melanocytic nevi, 67-68, 68tMelanonychia, longitudinal,
74-75, 74fMELTUMPs, 77-78Memory T cells, recruitment into
skin, 256-257Merkel cell carcinoma, nail unit, 56Mid-infrared lasers, in
photodynamic treatment ofacne, 24
Mohs micrographic surgeryfor cutaneous squamous
cell carcinoma, 141, 144, 144ffor melanoma of the nail unit, 54for squamous cell carcinoma of the
nail unit, 41-42, 45-46, 46fMolecular therapy, for epidermolysis
bullosa, 324-325Morbus Kostmann disease, 364Multifocal
lymphangioendotheliomatosis,176-178, 177f
Myofibromatosis, infantile, 173-175
NNail unit
anatomy and histology, 34-37basal cell carcinoma, 37-38longitudinal melanonychia, 74-75,
74fmalignant glomus tumors, 56melanoma
diagnosis, 48-52, 48f, 50tetiology, 47-48histology, 51-52incidence, 46-47staging, 52-53treatment, 53-56
Merkel cell carcinoma, 56sarcomas, 56squamous cell carcinoma
differential diagnosis, 39tetiology and risk factors, 38-41human papillomavirus in, 38-40,
40f
Index 381
Nail unit (cont.)treatment, 41-46, 42t, 43f, 44f,
45f, 46fNB-UVB (see Ultraviolet B,
narrowband)Near-infrared light, in photodynamic
treatment of acne, 10Necrolytic acral erythema, 112-115,
113f, 114f, 115fNephrogenic fibrosing dermopathy
clinical features, 123-124, 123f,125f
differential diagnosis, 124-125etiology, 123histopathologic features, 124, 124ftreatment, 126
Neuroblastomabiological markers, 162clinical features, 160, 160f, 161fetiology, 159histopathology, 161incidence, 159prognosis, 161-162skin involvement, 159-160
Neurocutaneous melanosis, 70-72,72f
Neutrophilic dermatosis, dorsalhands
associated systemic disorders,111-112
clinical features, 107-109, 109f,110f
differential diagnosis, 109, 111histopathologic features, 109, 110f,
111fmalignancies and, 111-112treatment, 111vasculitis in, 108-109
Nevimelanocytic (see Melanocytic nevi)MELTUMPs, 77-78Spitz, 74-77, 76f
Nevirapine, cutaneous side effects,289-290, 289t
NF-�B, in familial cylindromatosis,223-224
Nonnucleoside reverse transcriptaseinhibitors, cutaneous sideeffects, 289-290, 289t
Nonsteroidal anti-inflammatorydrugs (NSAIDs), cutaneousside effects, 292-294
Nucleoside reverse transcriptaseinhibitors, cutaneous sideeffects, 289t, 290-291
OOccult spinal dysraphism, 72-74,
73f, 73tOgna, variant of epidermolysis
bullosa simplex, 308(see also Epidermolysis bullosa;
Epidermolysis bullosasimplex)
Organ transplant recipients,cutaneous squamous cellcarcinoma in, 136-137,144-145, 145f
Oxcarbazepine, cutaneous sideeffects, 292
PPaclitaxel, cutaneous side effects,
285Palisaded neutrophilic and
granulomatous dermatitisclinical features, 102-103, 104fdifferential diagnosis, 104, 107histopathologic features, 104, 105f,
106-107, 106f, 107fParapsoriasis, narrowband
ultraviolet-B for, 243-244Paronychia, cetuximab therapy and,
282Pasini strain, dystrophic
epidermolysis bullosa, 313(see also Dystrophic epidermolysis
bullosa; Epidermolysis bullosa)Photodermatoses, narrowband
ultraviolet-B for, 240Phototherapy
for acne (see Acne, photodynamictreatment)
382 Index
for psoriasis (see Psoriasis,narrowband ultraviolet-Bphototherapy)
Pigmentary abnormalities, imatinibtherapy and, 284
Polycythemia vera, narrowbandultraviolet-B for pruritus in,240
Polymorphic light eruption,narrowband ultraviolet-Bfor, 240
Protease inhibitors, cutaneous sideeffects, 289, 289t
Protoporphyrin IX, 8-10, 9fPruritus, narrowband ultraviolet-B
for, 240Psoralen ultraviolet A (PUVA), vs.
narrowband ultraviolet-B, forpsoriasis, 239-240
Psoriasis�-defensins and, 367-368chemokines in, 262f, 263, 265-266histopathology, 264-265leukocyte recruitment in, 262fnarrowband ultraviolet-B
phototherapybiologic effects, 237vs. broadband ultraviolet-B, 237carcinogenesis risk, 240-241combined with systemic therapy,
242-243combined with topical therapy,
241-242dose, 237-238effectiveness, 239-240frequency, 239history, 236-237vs. psoralen ultraviolet A,
239-240safety, 240-241
Pulsed dye lasers, low fluence, inphotodynamic treatment ofacne, 15-16
Pulsed light, photochemicalinteractions, 12-13
Punch biopsy, in evaluation ofpigmented lesions of thenail unit, 50
PUVA (psoralen ultraviolet A), vs.narrowband ultraviolet-B, forpsoriasis, 239-240
RRadiography, in staging cutaneous
squamous cell carcinoma,138-139
Radiotherapy, for cutaneoussquamous cell carcinoma,142-143
Retinoidsfor cutaneous squamous cell
carcinoma, 142with narrowband ultraviolet-B
phototherapy for psoriasis,242, 243
Rhabdomyosarcomadifferential diagnosis, 163-164histopathology, 163incidence, 162location, 163prognosis, 164-165skin involvement, 163, 164
Rheumatoid arthritis, cutaneoussquamous cell carcinoma in,146-147, 146f
Rheumatoid papules, 102
SSarcomas, nail unit, 56Sebaceous glands
in acne, 6indocyanine green dye and, 23-24
Sentinel lymph node biopsyfor Spitz nevi, 199for staging cutaneous squamous
cell carcinoma, 139-140for staging melanoma of the nail
unit, 53for staging MELTUMPs, 77-78
Spiradenomaclinical features, 226-227histopathology, 227-229, 228f
Index 383
Spiradenoma (cont.)history, 226pathogenesis, 229
Spitz neviatypical, 195-197, 196f, 198tbiological behavior, 197clinical features, 194, 194fdiagnosis, 75-77, 76fgenomic and genetic changes,
86-89, 87f, 88f, 95, 96f, 197histopathology, 195-196, 195f, 196fimmunoprofile, 197treatment, 199, 199t
Squamous cell carcinomacutaneous
case studies, 144-149, 144f, 145f,146f, 147f, 148f
metastasis risk inhost factors associated with,135-138, 137ttumor characteristicsassociated with, 134-135, 134t
risk in epidermolysis bullosa, 321staging options, 138-140, 138ttreatment
adjuvant therapy, 142-143follow-up, 143surgical removal, 140-142
nail unitdifferential diagnosis, 39tetiology and risk factors, 38-41human papillomavirus in, 38-40,
40ftreatment, 41-46, 42t, 43f, 44f,
45f, 46fStaging
MELTUMPs, 77-78nail unit melanoma, 52-53squamous cell carcinoma, 138-140
Stem cells, epidermal (see Epidermalstem cells)
Sunscreens, UVA protection from,68-69, 69t
Sweet’ s syndrome, 107-108, 111
TT-cell lymphoma, narrowband
ultraviolet-B for, 243-244T cells
chemokine receptors and, 255-256(see also Chemokines)
memory, recruitment into skin,256-257
Taxanes, cutaneous side effects, 285Tazarotene, for psoriasis, 242Ticlopidine, cutaneous side effects,
294TLRs (Toll-like receptors), 359TNF (tumor necrosis
factor)-� antagonists, cutaneousside effects, 285-288, 286t
Toll-like receptors (TLRs), 359Transplant recipients, cutaneous
squamous cell carcinoma in,144-145, 145f
Trichoepitheliomaclinical features, 229histopathology, 230-231, 230fpathogenesis, 231
Tufted angioma, 210Tumid lupus erythematosus
clinical features, 118-120, 119fdifferential diagnosis, 121-122histopathology, 120-121, 120f, 121f
Tumor necrosis factor (TNF)-�antagonists, cutaneous sideeffects, 285-288, 286t
Turban tumor syndrome (seeFamilial cylindromatosis)
UUltraviolet A
in light treatment of acne, 9-10protection by sunscreens, 68-69, 69tin squamous cell carcinoma of
the nail bed, 40Ultraviolet B, narrowband (NB-UVB)
for acquired perforatingdermatosis, 246
384 Index
for atopic dermatitis, 245-246for cutaneous T-cell lymphoma and
parapsoriasis, 243-244for lichen planus, 245for photodermatoses, 246for polycythemia vera–associated
pruritus, 246-247for psoriasis (see Psoriasis,
narrowband ultraviolet-Bphototherapy)
for vitiligo, 244-245
VVascular anomalies, in infants and
childrenclassification, 199-201, 200themangiomas (see Hemangiomas,
infantile)kaposiform hemangioendothelioma,
208, 209fKasabach-Merritt phenomenon,
206-207, 207ftufted angioma, 210
Venous malformations, vs.glomuvenous malformations,184-185, 184t
Violaceous skin lesions, neonatalblue rubber bleb nevus
syndrome (see Blue rubberbleb nevus syndrome)
congenital leukemia (see Leukemia,congenital)
dermal hematopoiesis, 155-156,155f
differential diagnosis, 154-156, 154tglomangioma/glomuvenous
malformation (seeGlomangioma/glomuvenousmalformation)
hemangiomas (see Hemangiomas,infantile)
hemangiopericytomas, 173-175,174f
juvenile xanthogranulomas (seeJuvenile xanthogranulomas)
Langerhans cell histiocytosis (seeLangerhans cell histiocytosis)
multifocallymphangioendotheliomatosis,176-178, 177f
myofibromatosis, 173-175neuroblastoma (see Neuroblastoma)rhabdomyosarcoma (see
Rhabdomyosarcoma)Visible light
photochemical interactions, 13-15in photodynamic treatment of
acne, 10Vitiligo, narrowband ultraviolet-B
for, 244-245
WWeber-Cockayne variant,
epidermolysis bullosa simplex,307, 308f
(see also Epidermolysis bullosa;Epidermolysis bullosasimplex)
Wound infections�-defensins and, 367LL-37 activity in, 361-362
ZZidovudine, cutaneous side effects,
289t, 291
Index 385
